CAR T-Cell Therapy Shows Promise in Advanced Kidney Cancer
ORLANDO — An off-the-shelf, allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting CD70 demonstrated antitumor activity in patients with advanced clear cell renal cell carcinoma (RCC), according to results from the phase I TRAVERSE trial. Three of 18 efficacy-evaluable patients (17%) responded to treatment with ALLO-316, and the disease control rate (DCR) reached 89%, reported […]
Oral Drug Shows Benefit for Notalgia Paresthetica in Mid-Stage Trial
A selective kappa opioid receptor agonist in patients with notalgia paresthetica led to “modestly” greater improvements in itchiness over placebo, but was associated with adverse events, a randomized phase II trial showed. At 8 weeks, improvements in average itchiness was significantly greater with oral difelikefalin (Korsuva) versus placebo on the Worst Itch Numeric Rating Scale […]
T-Cell Receptor Gene Therapy Shows Promise in Pancreatic Cancer
A novel T-cell receptor (TCR) gene therapy may be effective in treating patients with pancreatic cancer and other cancers that express the KRAS G12D mutation, researchers have found. Their case study — published in the New England Journal of Medicine (NEJM) — showed that a heavily pretreated patient with pancreatic ductal adenocarcinoma achieved a deep […]
Study shows how bioactive substance inhibits important receptor: Results raise hope for new drugs against cancer and brain diseases
The A2A receptor regulates how vigorously the innate immune system attacks diseased cells. Researchers at the University of Bonn have now been able to show for the first time how an important inhibitor binds to the receptor. In the future, the results will facilitate the targeted search for molecules that give the innate immune system […]
How CAR T-Cell Therapy Measures Up in Follicular Lymphoma
In relapsed or refractory follicular lymphoma, treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel, Yescarta) was associated with better outcomes compared with currently available therapies, a comparative analysis of the ZUMA-5 and SCHOLAR-5 trials suggested. Overall response rate (ORR) was higher, and both progression-free survival (PFS) and overall survival (OS) were […]
Novel Migraine Prevention Drug Wins FDA Nod
Atogepant (Qulipta) became the first oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) specifically developed for migraine prevention to win FDA approval, AbbVie announced Monday. The drug earned a nod for prevention of episodic migraine in adults and became the second gepant approved for migraine prevention. The first, rimegepant (Nurtec ODT), originally was approved to […]
Anti-CD7 CAR-T Therapy Yields High Response Rate in Acute Leukemia
Donor-derived anti-CD7 chimeric antigen receptor (CAR) T-cell therapy led to complete responses in 18 of 20 patients with relapsed or refractory (r/r) T-cell acute lymphoblastic leukemia (ALL), a first-in-human clinical trial showed. After a median follow-up of 6.3 months, 15 of the 18 responding patients remained in remission, and seven patients had undergone stem-cell transplantation […]
Slow Going With CAR T-Cell Therapy for Solid Tumors
Almost 4 years after the first chimeric antigen receptor (CAR) T-cell therapies received FDA approval, the transformative impact of the treatment on refractory hematologic malignancies has yet to translate into the field of solid tumors. The increased molecular complexity of solid tumors and lack of good antigen targets have coalesced into a formidable roadblock for […]
‘Modest’ Erectile Dysfunction Benefit With GLP-1 Agonist
GLP-1 receptor agonist treatment in men with type 2 diabetes may thwart some new cases of erectile dysfunction, an exploratory analysis of a randomized trial suggested. The findings, from the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial, showed that slightly fewer men developed erectile dysfunction while on long-term treatment with once-weekly […]